Association between cigarette smoking and RASSF1A gene promoter hypermethylation in lung cancer patients: A metaanalysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8451-8454

  Wu, Xiao Ming ^a   Chen, Yu ^a   Shao, Yang ^a   Zhou, Xiao Long ^a   Tang, Wen Ru ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cigarette smoking; Lung cancer; Meta analysis; RASSF1A hypermethylation

Indexed keywords

RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADVERSE EFFECTS; CASE CONTROL STUDY; DNA METHYLATION; GENETICS; HUMAN; LUNG NEOPLASMS; META ANALYSIS; PROGNOSIS; PROMOTER REGION; RISK FACTOR; SMOKING;

CASE-CONTROL STUDIES; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEINS;

EID: 84923043525     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8451     Document Type: Article

References (25)

1. Burbee DG, Forgacs E, Zochbauer-Muller S, et al (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 93, 691-9.
2. Dammann R, Li C, Yoon JH, et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9.
3. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
4. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
5. Endoh H, Yatabe Y, Shimizu S, et al (2003). RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer, 106, 45-51.
6. Ge YZ, Xu LW, Jia RP, et al (2014). The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumour Biol, 35, 3881-90.
7. Grote HJ, Schmiemann V, Geddert H, et al (2006). Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer, 108, 129-34.
8. Hesson LB, Cooper WN, Latif F (2007). The role of RASSF1A methylation in cancer. Dis Markers, 23, 73-87.
9. Honorio S, Agathanggelou A, Schuermann M, et al (2003). Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene, 22, 147-50.
10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
11. Khokhlatchev A, Rabizadeh S, Xavier R, et al (2002). Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol, 12, 253-65.
12. Kim DH, Kim JS, Ji YI, et al (2003). Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res, 63, 3743-6.
13. Lin RK, Hsieh YS, Lin P, et al (2010). The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest, 120, 521-32.
14. Lin RK, Hsu HS, Chang JW, et al (2007). Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer, 55, 205-13.
15. Liu L, Tommasi S, Lee DH, et al (2003). Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene, 22, 8125-36.
16. Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24.
17. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
18. Mathe E (2004). RASSF1A, the new guardian of mitosis. Nat Genet, 36, 117-8.
19. Shivakumar L, Minna J, Sakamaki T, et al (2002). The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol, 22, 4309-18.
20. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
21. Tomizawa Y, Kohno T, Kondo H, et al (2002). Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res, 8, 2362-8.
22. Villeneuve PJ, Mao Y (1994). Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Public Health, 85, 385-8.
23. Vo LT, Thuan TB, Thu DM, et al (2013). Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer. Asian Pac J Cancer Prev, 14, 7713-8.
24. Wang SH, Liu NH, Wang J, et al (2008). Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer. Chin Med J (Engl), 121, 1712-21.
25. Zochbauer-Muller S, Fong KM, Virmani AK, et al (2001). Aberrant promoter methylation of multiple genes in nonsmall cell lung cancers. Cancer Res, 61, 249-55.